N@N

TLEO, MAPP, MBLX, MDSO, VOCS, CYTX Expected to Trade Up After Bullish Patterns Develop

April 20, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring top technical trading patterns and these stocks are the most likely to trade Up in the coming weeks. TALEO CORP-CLASS A (NASDAQ:TLEO), MAP PHARMACEUTICALS INC (NASDAQ:MAPP), METABOLIX INC (NASDAQ:MBLX), MEDIDATA SOLUTIONS INC (NASDAQ:MDSO), VOCUS INC (NASDAQ:VOCS), CYTORI THERAPEUTICS INC (NASDAQ:CYTX) are all expected to go Up as Bullish signals have been generated by top technical trading patterns. We monitor these patterns: Support Break, Support Reversal, Breakaway Gap, Measured Gap, Exhaustion Gap, Resistance Break, Resistance Reversal, Saucer Reversal, Volume Climax, Volume Trend, Fibonacci Reversal, Consolidation Breaks, Trend Line Break,Trend Line Reversal, Candles, Golden Crosses, Death Crosses and more. The chart below displays the stocks expected to go Up along with pattern, strategy and strength ratings.

     Symbol     Company                             Strategy                            Pattern Name            Strength  
     TLEO       TALEO CORP-CLASS A                  Breakout (Stocks) DO                Trend Line Reversal(5+)     3         
     MAPP       MAP PHARMACEUTICALS INC             Reversal (Stocks) DWC               Trend Line Break(3)     4         
     MBLX       METABOLIX INC                       Breakout (Stocks) DO                Rounded Top             1         
     MDSO       MEDIDATA SOLUTIONS INC              Reversal (Stocks) DWC               Trend Line Reversal(5+)     1         
     VOCS       VOCUS INC                           Reversal (Stocks) DWC               Broadening Reversal     1         
     CYTX       CYTORI THERAPEUTICS INC             Breakout (Stocks) DO                Rounded Top             1         

Chart Pattern Recognition is based on a 20-year patterns database. This database is used to determine pattern strength for patterns as they appear. There is no optimization and the pattern signals never change. For each pattern variation, we record accuracy and profitability statistics in a patterns database. From this information, we are able to define strength ratings from 1 to 5. The '1' rating shows ALL patterns while a '5' rating shows the best patterns according to profitability. Each pattern has its own strength rating factors. The result is an automatic ranking system that allows us to only show the BEST patterns. You can see that, at Strength 5, virtually all the patterns are profitable. The pattern strength rating system separates the most profitable patterns. The specific technology used to make these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/sw/ot.php

TALEO CORP-CLASS A (NASDAQ:TLEO) - Taleo Corporation provides on-demand talent management software solutions. Its products include Taleo Enterprise, which supports medium and large enterprises in talent management processes ranging from sourcing, recruiting, and onboarding to performance management, goals management, development planning, succession planning, and compensation; and Taleo Business Edition that supports smaller more centralized organizations, stand-alone departments and divisions of larger organizations, and staffing companies in recruiting, onboarding, performance management, and compensation activities. The company also operates online exchanges, including the Knowledge Exchange, an online social networking community that enables its customers to share and discuss talent management topics, product ideas, and best practices; the Solution Exchange, an online exchange that allows its customers to explore, evaluate, demo, and compare the products and services of its network of pre-integrated alliance partners; and the Talent Exchange, an opt-in marketplace where job seekers and employers connect to match job opportunities to a job seekers universal profile. In addition, it provides implementation, solution optimization and expansion, technical, and training services. The company serves organizations in the consumer goods, business services, energy, financial services, healthcare, manufacturing, technology, transportation, government, and retail sectors. Its software applications are offered to customers primarily on a subscription basis. The company sells subscriptions to its solutions through strategic partners, as well as directly in the United States, Canada, Europe, and Australia. It was formerly known as Recruitsoft, Inc. and changed its name to Taleo Corporation in March 2004. Taleo Corporation was incorporated in 1999 and is headquartered in Dublin, California.

MAP PHARMACEUTICALS INC (NASDAQ:MAPP) - MAP Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of inhalation therapies for patients suffering from migraine. It is developing LEVADEX, which is in Phase III clinical trials for the treatment of migraine through oral inhalation. The company is also developing two earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using its Tempo inhaler. MAP Pharmaceuticals, Inc. has collaborations and license agreements with Elan Pharma International Limited, Nektar Therapeutics UK Limited, Exemplar Pharmaceuticals, LLC, and Allergan Inc. The company was founded in 2003 and is based in Mountain View, California.

METABOLIX INC (NASDAQ:MBLX) - Metabolix, Inc., a bioscience company, develops and commercializes alternatives to petrochemical-based plastics, chemicals, and energy. The company offers a proprietary microbial fermentation system to produce a family of polymers known as polyhydroxyalkanoates under the Mirel name. Mirel offers biodegradability characteristics and could be used in a range of commercial applications, including products used in agriculture and horticulture, compost and organic waste diversion bags, marine and aquatic applications, consumer products, business equipment and durable goods, and general packaging materials. In addition, the company is also developing a proprietary platform technology for co-producing plastics, chemicals, and energy from crops, such as switchgrass, oilseeds, and sugarcane. It has a strategic alliance with ADM Polymer Corporation. The company was founded in 1992 and is based in Cambridge, Massachusetts.

MEDIDATA SOLUTIONS INC (NASDAQ:MDSO) - Medidata Solutions, Inc. provides hosted clinical development solutions for life science organizations worldwide. Its solutions include software and services that allow customers to achieve clinical results by streamlining the design, planning, and management of key aspects of the clinical development process, including protocol development, contract research organizations (CRO) negotiation, investigator contracting, the capture and management of clinical trial data, and the analysis and reporting of that data on a worldwide basis. The company primarily offers Medidata Rave, a comprehensive platform that integrates electronic data capture with a clinical data management system in a single solution. It also provides Medidata Designer application, a clinical trial protocol authoring tool that enables customers to write trial protocols and automatically configure Medidata Rave. In addition, the company offers Medidata Grants Manager, which enables its customers to benchmark their investigator budgets against industry data, as well as their own grant history; and Medidata CRO Contractor that focuses on benchmarks for CRO outsourcing, budgeting, and negotiation. Further, it provides professional services, including implementation services to meet customers data requirements for various indications; workflow design to meet the needs of various study phases and global regulatory requirements; and guidance on best practices for using its application services. The companys customers include pharmaceutical, biotechnology, and medical device companies; academic institutions; clinical research organizations; and other entities engaged in clinical trials. It markets and sells its application services through a direct sales force, and through relationships with CROs and other strategic partners. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.

VOCUS INC (NASDAQ:VOCS) - Vocus, Inc. provides on-demand software for public relations management. Its software addresses the critical functions of public relations including media relations, news distribution, and news monitoring. The companys software modules include Contact Management, which allows customers to access a database of journalists, media outlets, and publicity opportunities, as well as to create targeted lists, send messages by fax or mail, and track meetings and telephone calls; Collateral Management that provides a repository to store information, such as media kits, photographs, videos, annual reports, and executive biographies; and Project Management that facilitates organizing press releases, speaking engagements, and publicity events. Its software modules also comprise Newsrooms, which provides access to an organizations news, press releases, digital collateral, grassroots advocacy tools, and other public information; PRWeb Online Newswire that distributes news to online news sites and public; and Email Campaigns, which delivers interactive communications that provide online access to related collateral material, and to track and measure response rates and other campaign metrics. In addition, the companys software modules include Analytics & Measurement that transforms data about news coverage, public relations activities, and online newsroom statistics into insight about programs and results; and News On-Demand, which monitors news sources to identify and deliver relevant news coverage to customers based on individual criteria. It also offers professional services, such as data migration, training, and configuration services. As of December 31, 2009, Vocus served approximately 4,438 customers in the financial and insurance, technology, healthcare and pharmaceutical and retail and consumer products industries, as well as government agencies, not-for-profit organizations, and educational institutions. The company is headquartered in Lanham, Maryland.

CYTORI THERAPEUTICS INC (NASDAQ:CYTX) - Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Its core product, the Celution System, provides physicians with clinical grade stem and regenerative cells for use in the cosmetic and reconstructive surgery market. It also intends to offer the PureGraft System in the U.S as a medical device that prepares autologous fat grafts for use in aesthetic body contouring. The company also sells the StemSource family of products worldwide, including in the United States, for research, as well as for the cryopreservation and storage of ADRCs. It offers the StemSource System as a standalone product, or as a part of a comprehensive suite of systems, equipment, and protocols collectively referred to as a StemSource Cell Bank. The company also develops Celution System for applications in cardiovascular disease, wound healing, gastrointestinal disorders, stress urinary incontinence, liver and renal disease spinal disc degeneration, and pelvic health conditions. Cytori Therapeutics has strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was founded in 1996 and is headquartered in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net